Gery P. Guy

Gery P. Guy

Auto-generated profile, based on publicly available information

Gery P. Guy

Division of Overdose Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
GGGery P. Guy
Gery P. Guy
SMSteven R. Machlin
Steven R. Machlin
DEDonatus U. Ekwueme
Donatus U. Ekwueme
KYK. Robin Yabroff
K. Robin Yabroff

20 October 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GGGery P. Guy
Gery P. Guy
DEDonatus U. Ekwueme
Donatus U. Ekwueme
KYK. Robin Yabroff
K. Robin Yabroff
EDEmily C. Dowling
Emily C. Dowling
CLChunyu Li
Chunyu Li
KVKatherine S. Virgo
Katherine S. Virgo
Purpose: To present nationally representative estimates of the impact of cancer survivorship on medical expenditures and lost productivity among adults in the United States. Methods: Using the 2008 to 2010 Medical Expenditure Panel Survey, we identified 4,960 cancer survivors and 64,431 individuals without a history of cancer age ≥ 18 years. Direct medical costs were measured using annual health care expenditures and examined by source of payment and service type. Indirect morbidity costs were estimated from lost productivity as a result of employment disability, missed work days, and lost household productivity. We evaluated the economic burden of cancer survivorship by estimating excess costs among cancer survivors, stratified by time since diagnosis (recently diagnosed [≤ 1 year] and previously diagnosed [> 1 year]), compared with individuals without a history of cancer using multivariable regression models stratified by age (18 to 64 and ≥ 65 years), controlling for age, sex, race/ethnicity, education, and comorbidities. Results: In 2008 to 2010, the annual excess economic burden of cancer survivorship among recently diagnosed cancer survivors was $16,213 per survivor age 18 to 64 years and $16,441 per survivor age ≥ 65 years. Among previously diagnosed cancer survivors, the annual excess burden was $4,427 per survivor age 18 to 64 years and $4,519 per survivor age ≥ 65 years. Excess medical expenditures composed the largest share of the economic burden among cancer survivors, particularly among those recently diagnosed. Conclusion: The economic impact of cancer survivorship is considerable and is also high years after a cancer diagnosis. Efforts to reduce the economic burden caused by cancer will be increasingly important given the growing population of cancer survivors.

1 June 2014 in Health Affairs
Verified
Journal Article
Closed access
GGGery P. Guy
Gery P. Guy
KYK. Robin Yabroff
K. Robin Yabroff
DEDonatus U. Ekwueme
Donatus U. Ekwueme
ASAshley Wilder Smith
Ashley Wilder Smith
EDEmily C. Dowling
Emily C. Dowling
LRLisa C. Richardson
Lisa C. Richardson
Adolescent and young adult cancer survivors—those who were ages 15–39 at their first cancer diagnosis—have important health limitations. These survivors are at risk for higher health care expenditu...

1 November 2018 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
GGGery P. Guy
Gery P. Guy
KZKun Zhang
Kun Zhang

9 August 2019 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
GGGery P. Guy
Gery P. Guy
THTamara M. Haegerich
Tamara M. Haegerich
MEMary E. Evans
Mary E. Evans
JLJan L. Losby
Jan L. Losby
RYRandall Young
Randall Young
CJChristopher M. Jones
Christopher M. Jones
The CDC Guideline for Prescribing Opioids for Chronic Pain recommends considering prescribing naloxone when factors that increase risk for overdose are present (e.g., history of overdose or substance use disorder, opioid dosages ≥50 morphine milligram equivalents per day [high-dose], and concurrent use of benzodiazepines). In light of the high numbers of drug overdose deaths involving opioids, 36% of which in 2017 involved prescription opioids, improving access to naloxone is a public health priority. CDC examined trends and characteristics of naloxone dispensing from retail pharmacies at the national and county levels in the United States. CDC analyzed 2012-2018 retail pharmacy data from IQVIA, a health care, data science, and technology company, to assess U.S. naloxone dispensing by U.S. Census region, urban/rural status, prescriber specialty, and recipient characteristics, including age group, sex, out-of-pocket costs, and method of payment. Factors associated with naloxone dispensing at the county level also were examined. The number of naloxone prescriptions dispensed from retail pharmacies increased substantially from 2012 to 2018, including a 106% increase from 2017 to 2018 alone. Nationally, in 2018, one naloxone prescription was dispensed for every 69 high-dose opioid prescriptions. Substantial regional variation in naloxone dispensing was found, including a twenty-fivefold variation across counties, with lowest rates in the most rural counties. A wide variation was also noted by prescriber specialty. Compared with naloxone prescriptions paid for with Medicaid and commercial insurance, a larger percentage of prescriptions paid for with Medicare required out-of-pocket costs. Despite substantial increases in naloxone dispensing, the rate of naloxone prescriptions dispensed per high-dose opioid prescription remains low, and overall naloxone dispensing varies substantially across the country. Naloxone distribution is an important component of the public health response to the opioid overdose epidemic. Health care providers can prescribe or dispense naloxone when overdose risk factors are present and counsel patients on how to use it. Efforts to improve naloxone access and distribution work most effectively with efforts to improve opioid prescribing, implement other harm-reduction strategies, promote linkage to medications for opioid use disorder treatment, and enhance public health and public safety partnerships.

12 March 2021 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
GGGery P. Guy
Gery P. Guy
This report describes changes in COVID-19 case and death growth rates associated with mask mandates and on-premises restaurant dining.